Expressing support for the designation of the week of May 3, 2026, through May 9, 2026, as "Tardive Dyskinesia Awareness Week".

Whereas many people living with serious mental illnesses (for example, bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder) or gastrointestinal disorders (for example, gastroparesis, upset stomach, nausea, and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics;
Whereas, while ongoing treatment with these medications can be necessary, prolonged use may be associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, and fingers or toes;
Whereas even mild symptoms of TD can impact people physically, socially, and emotionally;
Whereas it is estimated that TD affects approximately 600,000 people in the United States, and approximately 60 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms;
Whereas it is important that people taking these medications be monitored for TD by a health care provider, and regular screening for TD is recommended by the American Psychiatric Association;
Whereas clinical research has led to approval of treatments for adults with TD by the Food and Drug Administration, and recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; and
Whereas the House of Representatives can raise awareness of TD among the public and medical community: Now, therefore, be it
That the House of Representatives—
expresses support for the designation of Tardive Dyskinesia Awareness Week; and
encourages each individual in the United States to become better informed about and aware of tardive dyskinesia.